What the studies show
Two-visit double-blind crossover in 32 premenopausal women: kisspeptin infusion increased activation in sexual-processing brain regions on fMRI and reduced sexual aversion scores. A mechanism study, not a treatment trial.
A few small or poorly-controlled human studies. Enough to be interesting; not enough to count on. Most of what gets called “clinically proven” online lives here.
- 1Thurston L, et al. Effects of kisspeptin administration in women with hypoactive sexual desire disorder: a randomized clinical trial.JAMA Netw Open, 2022; DOI 10.1001/jamanetworkopen.2022.3613132 premenopausal women, double-blind crossover.
In context
Kisspeptin is the hormone that switches on the reproductive axis: it makes the hypothalamus release GnRH, which drives LH, FSH and the sex hormones. In people it reliably raises LH within minutes, has been used as an egg-maturation trigger in IVF in phase 2 trials, and in two small randomised crossover trials at Imperial College London (32 women, 32 men) increased sexual-brain activation and reduced sexual aversion in people with low sexual desire. All of that is research-scale. It is not an approved medicine anywhere and is prohibited for male athletes.
Kisspeptin is not approved. Legal status differs by country — see the regulation section or the jurisdiction pages.
Questions
Is Kisspeptin proven to help with sexual desire?
What studies are behind the grade?
Is Kisspeptin approved for this?
Other outcomes for Kisspeptin
- BLH and testosterone releaseMany small studies
- CIVF egg maturation trigger2 phase 2 trials
- CSexual desire and arousal (men with HSDD)1 crossover RCT (n=32)
- CSafetyadverseSmall studies
Reviewed 3 September 2026. Grades count human evidence only; see how LYO grades. Not medical advice. Correct this page →